Vineet Laboratories Ltd. (VINEETLAB) — NSE Stock Analysis
Sector: Basic Materials. Industry: Chemicals. Share price: ₹33.65.
Company Overview
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and fine chemicals in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was founded in 2007 and is based in Hyderabad, India.
Valuation Snapshot
- Market cap: —
- P/E: —
- P/B: —
- ROE: —
Blanket Finance is not a SEBI-registered investment adviser or research analyst. This content is for educational and informational purposes only.